
The global cancer supportive care products market report deals with cancer supportive care drugs, which can be defined as products or drugs that are mainly used for treatment of adverse effects associated with cancer therapy as well as for the treatment of the symptoms and signs of cancer drugs, such as chemotherapy-induced nausea and vomiting, chemotherapy induced neutropenia, chemotherapy-induced anemia, hair loss, etc. On the basis of drug classes, the market has been segmented into non-steroidal anti-inflammatory drugs, anti-infective, anti-emetics, monoclonal antibodies, erythropoietin stimulating agents, opioid analgesics, bisphosphonates, and granulocyte colony stimulating factors. The global cancer supportive care products market is expected to expand at a CAGR of 4.3% over the forecast period (2015–2021) to account for US$ 31,700 Mn by 2021.